1 Executive Summary
1.1 Report Scope
1.2 Definitions
1.2.1 Alzheimer’s Disease
1.2.2 Parkinson’s Disease
1.2.3 Multiple Sclerosis
1.2.4 Amyotrophic Lateral Sclerosis
1.2.5 Huntington’s Disease
1.2.6 Neuropathies
1.3 Report Methodology
1.4 The Market
1.5 Market Composition
1.6 Competitive Profiles
1.7 Factors to Growth
2 The Market
2.1 Global Pharmaceutical Market
2.2 Global Neurodegenerative Market
2.3 Market Size and Growth
2.4 Market Composition
2.5 US/North American Market
2.5.1 Overview
2.5.2 US Neurodegenerative Market
2.5.3 Canadian Neurodegenerative Market
2.5.4 Regulatory Scenario
2.6 European Market
2.6.1 Overview
2.6.2 Regulatory Scenario
2.7 Japanese Market
2.7.1 Overview
2.7.2 Japanese Neurodegenerative Market
2.7.3 Regulatory Scenario
3 Market Composition: Alzheimer’s Disease
3.1 Overview
3.2 Risk Factors
3.3 Symptoms
3.4 Therapies
3.5 Market Size and Growth
3.6 Market Composition
3.7 By Region
3.8 Major Players
3.9 Anti-Alzheimer’s Disease Products
3.9.1 AChE inhibitors
3.9.2 NMDA Antagonists
3.10 Incidence of Alzheimer’s Disease
3.11 In the Pipeline
3.12 Looking Ahead
3.13 Key Clinical Trials
3.14 Key Emerging Therapies
3.15 Research and Development Trends
4 Market Composition: Parkinson’s Disease
4.1 Overview
4.2 Risk Factors
4.3 Symptoms
4.4 Therapies
4.5 Market Size and Growth
4.6 Market Composition by Region
4.7 Major Players
4.8 Anti-Parkinson’s Disease Products
4.8.1 Anticholinergics
4.8.2 COMT Inhibitors
4.8.3 Combination Anti-Parkinson’s Agents
4.8.4 Dopamine Receptor Agonists
4.8.5 Carbidopa Levodopa Preparations
4.8.6 MAO-B inhibitors
4.8.7 Amantadine
4.9 Incidence and Prevalence of Parkinson’s Disease
4.10 In the Pipeline
4.11 Looking Ahead
4.12 Key Clinical Trials
4.13 Key Emerging Therapies
4.14 Key Types of Therapies in Development
5 Market Composition: Multiple Sclerosis
5.1 Overview
5.2 Risk Factors
5.3 Symptoms
5.4 Therapies
5.5 Market Size and Growth
5.6 Market Composition
5.7 Major Players
5.8 Multiple Sclerosis Products
5.8.1 Avonex
5.8.2 Betaseron
5.8.3 Rebif
5.8.4 Copaxone
5.8.5 Novantrone
5.8.6 Symptomatic Relief
5.9 Incidence of Multiple Sclerosis
5.10 In the Pipeline
5.11 Looking Ahead
5.12 Key Emerging Therapies
5.13 Key Late-Stage Clinical Therapeutics
5.14 Key Clinical Trials
6 Market Composition: Amyotrophic Lateral Sclerosis
6.1 Overview
6.2 Risk Factors
6.3 Symptoms
6.4 Therapies
6.5 Major Players
6.6 Anti-Amyotrophic Lateral Sclerosis Products
6.7 Incidence of Anti-Amyotrophic Lateral Sclerosis
6.8 In the Pipeline
6.9 Key Emerging Therapies
6.10 Key Clinical Trials
7 Market Composition: Huntington’s Disease
7.1 Overview
7.2 Risk Factors
7.3 Symptoms
7.4 Therapies
7.5 Market Size and Growth
7.6 Market Composition by Region
7.7 Major Players
7.8 Anti-Huntington’s Disease Products
7.8.1 Neuroleptics
7.8.2 Benzodiazepines
7.9 Incidence of Huntington’s Disease
7.10 In the Pipeline
7.11 Key Emerging Therapies
8 Neuropathies
8.1 Overview
8.2 Risk Factors
8.3 Symptoms
8.4 Therapies
8.5 Market Size and Growth
8.6 Anti-Neuropathies Products
8.6.1 Anticonvulsants
8.6.2 Antidepressants
8.6.3 Analgesics
8.6.4 Others
8.7 Incidence of Neuropathies
8.8 In the Pipeline
8.9 Looking Ahead
8.10 Key Emerging Therapies
8.11 Key Clinical Trials
9 Competitive Profiles
9.1 Amarin
9.1.1 Product Pipeline
9.1.2 Key Financials
9.2 AstraZeneca
9.2.1 Product Portfolio
9.2.2 Product Pipeline
9.2.3 Key Financials
9.3 Avanir
9.3.1 Product Portfolio
9.3.2 Product Pipeline
9.3.3 Key Financials
9.4 Avigen
9.4.1 Product Pipeline
9.4.2 Key Financials
9.5 Biogen Idec
9.5.1 Product Portfolio
9.5.2 Product Pipeline
9.5.3 Key Financials
9.6 Boehringer Ingelheim
9.6.1 Product Portfolio
9.6.1.1 Key Financials
9.7 Daiichi Sankyo
9.7.1 Product Portfolio
9.7.2 Key Financials
9.8 Eisai
9.8.1 Product Portfolio
9.8.2 Product Pipeline
9.8.3 Key Financials
9.9 Elan
9.9.1 Product Portfolio
9.9.2 Product Pipeline
9.9.3 Key Financials
9.10 Eli Lilly
9.10.1 Product Portfolio
9.10.2 Product Pipeline
9.10.3 Key Financials
9.11 Forest Laboratories
9.11.1 Product Portfolio
9.11.2 Product Pipeline
9.11.3 Key Financials
9.12 Genzyme
9.12.1 Product Pipeline
9.12.2 Key Financials
9.13 GlaxoSmithKline
9.13.1 Product Portfolio
9.13.2 Product Pipeline
9.13.3 Key Financials
9.14 Guilford Pharmaceuticals/MGI Pharma
9.14.1 Product Pipeline
9.14.2 Key Financials
9.15 IVAX
9.15.1 Product Portfolio
9.15.2 Key Financials
9.16 Johnson & Johnson
9.16.1 Product Portfolio
9.16.2 Product Pipeline
9.16.3 Key Financials
9.17 Kyowa Hakko Kogyo
9.17.1 Product Portfolio
9.17.2 Product Pipeline
9.17.3 Key Financials
9.18 Lundbeck
9.18.1 Product Portfolio
9.18.2 Product Pipeline
9.18.3 Key Financials
9.19 Merck KGaa
9.19.1 Product Portfolio
9.19.2 Product Pipeline
9.19.3 Key Financials
9.20 Mitsubishi Pharma
9.20.1 Product Portfolio
9.20.2 Product Pipeline
9.20.3 Key Financials
9.21 Novartis
9.21.1 Product Portfolio
9.21.2 Product Pipeline
9.21.3 Key Financials
9.22 Pain Therapeutics
9.22.1 Product Pipeline
9.22.2 Key Financials
9.23 Pfizer
9.23.1 Product Portfolio
9.23.2 Product Pipeline
9.23.3 Key Financials
9.24 Prestwick Pharmaceuticals
9.24.1 Product Pipeline
9.25 Roche
9.25.1 Product Pipeline
9.25.2 Key Financials
9.26 Sanofi-Aventis
9.26.1 Product Portfolio
9.26.2 Product Pipeline
9.26.3 Key Financials
9.27 Schering AG
9.27.1 Product Portfolio
9.27.2 Product Pipeline
9.27.3 Key Financials
9.28 Shire Plc
9.28.1 Product Portfolio
9.28.2 Product Pipeline
9.28.3 Key Financials
9.29 Solvay
9.29.1 Product Portfolio
9.29.2 Product Pipeline
9.29.3 Key Financials
9.30 Takeda
9.30.1 Product Pipeline
9.30.2 Key Financials
9.31 Teva
9.31.1 Product Portfolio
9.31.2 Product Pipeline
9.31.3 Key Financials
9.32 Valeant Pharmaceuticals
9.32.1 Product Portfolio
9.32.2 Product Pipeline
9.32.3 Key Financials
9.33 Wyeth
9.33.1 Product Portfolio
9.33.2 Product Pipeline
9.33.3 Key Financials
10 Factors to Growth
10.1 Demographic
10.2 Healthcare Spends
10.3 Disease Conditions
10.4 Patent Expiry of Popular Products
10.5 New Drug Therapies
10.6 Growth of Generics
10.6.1 Key Facts about Generics
10.6.2 Generics in the Future
Appendix A: Patent Expiries
Appendix B: Alzheimer’s Disease Clinical Research
Appendix C: Parkinson’s Disease Clinical Research
Appendix D: Multiple Sclerosis Clinical Research
Appendix E: Amyotrophic Lateral Sclerosis Clinical Research
Appendix F: Huntington’s Disease Clinical Research
Appendix G: Neuropathies Clinical Research
Appendix H: Notes on Related Dementias (RD)
Appendix I: Notes on Parkinsonism
Tables
Table 10.2 World Market for Neurodegenerative Drug, 2006-2010 ($ mn)
Table 2.1 United States Health Insurance Expenditures by Type of Expenditure
Table 2.2 Visits made to physicians by age group and sex (%)
Table 2.3 Usage of Prescription Drugs by Type
Table 2.4 Cholinesterase Inhibitors Expenditure per 1000 Persons Aged 65
Table 3.1 World Market for Alzheimer’s Disease by Region, 2005 ($)
Table 3.2 Global Sales (2001 - 2005) - Aricept ($ mn)
Table 3.3 Global Sales Forecast (2006-2010) - Aricept ($ mn)
Table 3.4 Global Sales (2001 - 2005) - Exelon ($ mn)
Table 3.5 Global Sales Forecast (2006-2010) - Exelon ($ mn)
Table 3.6 Global Sales (2001 - 2005) - Reminyl ($ mn)
Table 3.7 Global Sales Forecast (2006-2010) - Reminyl ($ mn)
Table 3.8 Global Sales Forecast (2004-2010) - Namenda/Ebixia ($ mn)
Table 3.9 Alzheimer’s Disease Incidence
Table 3.10 Prevalence of Alzheimer’s Disease - (Million)
Table 3.11 Alzheimer’s Disease Pipeline
Table 3.12 World Market for Anti-Alzheimer’s Products, 2006-2010 ($ mn)
Table 4.1 World Market for Parkinson’s Disease by Region, 2005 ($)
Table 4.2 Global Sales Forecast - Comtan ($ mn)
Table 4.3 Global Sales Forecast - Tasmar ($mn)
Table 4.4 Global Sales Forecast - Stalevo ($ mn)
Table 4.5 Global Sales Forecast - Mirapex/Sifrol ($mn)
Table 4.6 Global Sales - Requip ($ mn)
Table 4.7 Global Sales Forecast - Requip ($ mn)
Table 4.8 Prevalence of Parkinson’s Disease (mn)
Table 4.9 Parkinson’s Disease Pipeline
Table 4.10 World Market for Anti-Parkinson’s Products, 2006-2010 ($ mn)
Table 4.11 Available and Emerging Drugs for Parkinson’s Disease
Table 5.1 Global Sales - Avonex ($ mn)
Table 5.2 Global Sales Forecast - Avonex ($ mn)
Table 5.3 Global Sales - Betaseron ($ mn)
Table 5.4 Global Sales Forecast - Betaseron ($ mn)
Table 5.5 Global Sales - Rebif ($ mn)
Table 5.6 Global Sales forecast - Rebif ($ mn)
Table 5.7 Global Sales - Copaxone ($ mn)
Table 5.8 Global Sales Forecast - Copaxone ($ mn)
Table 5.9 Multiple Sclerosis Pipeline
Table 5.10 Forecast of Multiple Sclerosis Drug Market, 2006-2010 ($ mn)
Table 6.1 Amyotrophic Lateral Sclerosis Pipeline
Table 7.1 Global Sales Forecast - Risperdal ($ mn)
Table 7.2 Huntington’s Disease Pipeline
Table 8.1 Global Sales - Tegretol ($ mn)
Table 8.2 Global Sales Forecast - Tegretol ($ mn)
Table 8.3 Global Sales - Neurontin ($ mn)
Table 8.4 Global Sales Forecast - Neurontin ($ mn)
Table 8.5 Global Sales Forecast - Cymbalta ($ mn)
Table 8.6 Global Sales Forecast - Lyrica ($ mn)
Table 8.7 Neuropathies Pipeline
Table 8.8 Global Neuropathic Pain Market ($ mn)
Table 9.1 Companies Active in Neurodegenerative Research, by Condition
Table 10.1 Major US Patent Expiries 2005-2007
Graphs
Graph 2.1 Global Pharmaceutical Sales 2001-2005
Graph 2.2 Global Pharmaceutical Sales by Region, 2005**
Graph 2.3 Leading Products by Global Pharmaceutical Sales, 2005**
Graph 2.4 Leading Therapy Classes by Global Pharmaceutical Sales, 2005**
Graph 2.5 Number of Parkinson Drug Prescriptions Dispensed
Graph 2.6 Recommended Drug Therapies for Parkinson’s Disease
Graph 3.1 World Market for Alzheimer’s Disease by Region, 2005 (%)
Graph 3.2 Alzheimer’s Disease Prevalence
Graph 4.1 World Market for Parkinson’s Disease by Region, 2005 (%)
Graph 5.1 Market Share of Leading Multiple Sclerosis Therapies, 2005
Graph 8.1 Top Causes of Pain
Graph 10.1 Percentage Increase in Age 60 and Over by Region, 2000-2050
Graph 10.2 World Aging Trends
Graph 10.3 Health Spending in Organization for Economic Co-operation and
Development (OECD) Countries as % of GDP, 2003
Graph 10.4 Government Expenditure on Health
Graph 10.5 U.S. Growth of Generics, 1984-2005
Graph 10.6 U.S. Generics vs. Brand-Name Pharmaceuticals Sales, 2005
Graph 10.7 Generic Drug Sales in U.S. (projected)
